Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin's disease: A Southwest Oncology Group phase II study

Thomas P Miller, S. E. Jones, J. M. Rainey

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The CHOP combination is active as evidenced by the objective response rate of 100% obtained in this study of patients with advanced HD. It is interesting that despite the low CR rate obtained with CHOP, seven of 12 patients are currently free of disease after having received MOPP following tumor-burden reduction with CHOP. Such an observation may warrant a trial of CHOP alternating with MOPP as initial treatment for advanced HD.

Original languageEnglish (US)
Pages (from-to)739-740
Number of pages2
JournalCancer Treatment Reports
Volume67
Issue number7-8
StatePublished - 1983

Fingerprint

Vincristine
Prednisone
Hodgkin Disease
Doxorubicin
Cyclophosphamide
Tumor Burden
Observation
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{4528e0e352cf44b98457db889cf72141,
title = "Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin's disease: A Southwest Oncology Group phase II study",
abstract = "The CHOP combination is active as evidenced by the objective response rate of 100{\%} obtained in this study of patients with advanced HD. It is interesting that despite the low CR rate obtained with CHOP, seven of 12 patients are currently free of disease after having received MOPP following tumor-burden reduction with CHOP. Such an observation may warrant a trial of CHOP alternating with MOPP as initial treatment for advanced HD.",
author = "Miller, {Thomas P} and Jones, {S. E.} and Rainey, {J. M.}",
year = "1983",
language = "English (US)",
volume = "67",
pages = "739--740",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "7-8",

}

TY - JOUR

T1 - Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin's disease

T2 - A Southwest Oncology Group phase II study

AU - Miller, Thomas P

AU - Jones, S. E.

AU - Rainey, J. M.

PY - 1983

Y1 - 1983

N2 - The CHOP combination is active as evidenced by the objective response rate of 100% obtained in this study of patients with advanced HD. It is interesting that despite the low CR rate obtained with CHOP, seven of 12 patients are currently free of disease after having received MOPP following tumor-burden reduction with CHOP. Such an observation may warrant a trial of CHOP alternating with MOPP as initial treatment for advanced HD.

AB - The CHOP combination is active as evidenced by the objective response rate of 100% obtained in this study of patients with advanced HD. It is interesting that despite the low CR rate obtained with CHOP, seven of 12 patients are currently free of disease after having received MOPP following tumor-burden reduction with CHOP. Such an observation may warrant a trial of CHOP alternating with MOPP as initial treatment for advanced HD.

UR - http://www.scopus.com/inward/record.url?scp=0020966707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020966707&partnerID=8YFLogxK

M3 - Article

C2 - 6688200

AN - SCOPUS:0020966707

VL - 67

SP - 739

EP - 740

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 7-8

ER -